Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Thrombosis clinical trials
Every US clinical trial registered for Thrombosis — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
30 US clinical trials · 7 currently recruiting
The research picture
Thrombosis has 30 registered US clinical trials, 7 of them open to new participants right now — about 23% of the total.
- 7
- recruiting participants now
- 23%
- of trials open to enrollment
- 5
- in Phase 3–4 (later-stage)
- 4
- top sponsor: Bristol-Myers Squibb
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
American Thrombosis and Hemostasis Network
NCT04398628
Neonatal Platelet Transfusion Threshold Trial
NICHD Neonatal Research Network
NCT06676904
Vascular Lab Resource (VLR) Biorepository
The Cleveland Clinic
NCT05628948
Pharmacogenomics of Warfarin in Hispanics and Latinos
University of Arizona
NCT02972385
Platelet Volunteers, Longitudinal and Multi-omic Study
National Heart, Lung, and Blood Institute (NHLBI)
NCT07137429
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
NCT03830320
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
Boston Children's Hospital
NCT06434207
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
University of Chicago
NCT00203970
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
Icahn School of Medicine at Mount Sinai
NCT06618976
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
Medco Health Solutions
NCT00830570
Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement
University of Chicago
NCT01988766
Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
Duke University
NCT00237328
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Daiichi Sankyo
NCT00398216
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
University of Utah
NCT04305756
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
ARCA Biopharma
NCT00073554
Prevalence of MTHFR Polymorphisms in Venous Disease
Health Diagnostic Laboratory
NCT01993914
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
The Medicines Company
NCT00043940
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
Scott C. Woller, MD
NCT02295475
Study Of Angiomax In Infants Under Six Months With Thrombosis
The Medicines Company
NCT00043277
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Encysive Pharmaceuticals
NCT00039858
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
Bristol-Myers Squibb
NCT03196206
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Aronora
NCT03453060
Sildenafil To Prevent Clot
Montefiore Medical Center
NCT03199612
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
Pfizer
NCT00914641
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Bristol-Myers Squibb
NCT02671461
PFA-100 Responsive to Effect of Energy Drinks on Platelet Function
St. Louis University
NCT02997111
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Thomas Jefferson University
NCT02270918
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
Bristol-Myers Squibb
NCT03939702
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Bristol-Myers Squibb
NCT02902679
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
ARCA Biopharma
NCT00322270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Thrombosis Trial Landscape
ClinicalTrials.gov lists 30 US studies indexed under Thrombosis, and 7 of those are currently open to recruitment — roughly 23% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Thrombosis shows 5 late-stage studies (Phase 3 and Phase 4 combined) alongside 12 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Thrombosis is led by Bristol-Myers Squibb with 4 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 30 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Thrombosis?
PlainTrial tracks 30 US clinical trials for Thrombosis, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Thrombosis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.